Navigation Links
Biotest Pharmaceuticals Corporation Announces Management Team
Date:12/4/2007

BOCA RATON, Fla., Dec. 4 /PRNewswire/ -- Biotest Pharmaceuticals Corporation, a leading developer of immunology biotherapeutic products, today announced the company's new management team as part of the formal completion of Biotest AG's acquisition of Nabi Pharmaceuticals (Nasdaq: NABI) and the creation of Biotest Pharmaceuticals. Please see the separate press release, "Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit," December 4, 2007 for more information.

"The team that we have assembled to run Biotest Pharmaceuticals represents leaders from both Biotest AG and Nabi Pharmaceuticals. They are proven professionals and bring to our new company extensive expertise in research, development and business management," said Professor Dr. Gregor Schulz, Chairman of the Management Board of Biotest AG. "We are confident that, led by this team, Biotest Pharmaceuticals will become a U.S. leader in the immunology biotherapeutic field."
Biotest Pharmaceuticals will be led by the following management team:

-- Chief Executive Officer - Rainer Pabst, PhD. Dr. Pabst is a biochemist

who previously served as Managing Director of Biotest Pharma GmbH.

Prior to that, he served as Vice President, Technical Operations for

Bayer Corp. Biological Products, Vice President Industrial Operations

at Centeon Pharma GmbH, and Head of Plasma Proteins Production at

Behringwerke AG. In his role as CEO, Dr. Pabst will be responsible for

the executive leadership and the operational execution of Biotest

Pharmaceuticals.

-- Chief Financial Officer - Jordan I. Siegel, CPA, MBA. Mr. Siegel

previously served as Senior Vice President, Finance, Chief Financial

Officer and Treasurer for Nabi Biopharmaceuticals. Prior to joining

Nabi, he served as Vice President of Finance for IVAX Pharmaceuticals,

Inc and previously as IVAX's Vice President and Treasurer. In his role

as CFO, Mr. Siegel will be responsible for the financial management and

reporting of Biotest Pharmaceuticals. To facilitate the transition

period for Nabi Biopharmaceuticals, Mr. Siegel also will continue to

hold the position of CFO at Nabi through March 2008.

-- Vice President of Project Management - Peter Seith. Mr. Seith

previously served as one of the Directors of Project Management for

Biotest Pharma GmbH. Prior to that, he was the Director of Quality

Assurance at CSL Behring. Mr. Seith will serve a dual role responsible

for both project management for Biotest Pharmaceuticals in Boca Raton

and Vice President of Corporate Quality Assurance for Biotest Pharma

worldwide.

"Biotest Pharmaceuticals draws upon the success and experience of two established leaders in the field of immunology and plasma products -- our parent company, Biotest AG, and Nabi Biopharmaceuticals," said Dr. Rainer Pabst, Chief Executive Officer of Biotest Pharmaceuticals. "With the completion of our acquisition of Nabi's Biologics business, pipeline and key assets, we feel we are founding Biotest Pharmaceuticals with a solid foundation, a high quality workforce, state-of-the-art facilities and a promising pipeline of biotherapeutic products. We look forward to realizing our potential and driving the growth of Biotest Pharmaceuticals as we move forward together."

About Biotest Pharmaceuticals Corporation

Biotest Pharmaceuticals Corporation develops and manufactures pharmaceutical and biotherapeutic products with a specialization in immunology. Biotest Pharmaceuticals will offer the hyperimmunoglobulin Nabi- HB(R), a key product used in the prevention of hepatitis B. Biotest Pharmaceuticals also is currently working to develop additional products including a polyvalent immunoglobulin (IVIG, Phase III) and Civacir(R) (Phase IIb), for the prevention of hepatitis C in liver transplant patients. Biotest Pharmaceuticals was formed in 2007 as part of the Biotest AG acquisition of Nabi Pharmaceuticals' Biologics business unit, including its plasmapheresis centers across the United States. The company employs approximately 500 people in the U.S. Biotest Pharmaceuticals is a subsidiary of Biotest AG, a German-based global provider of plasma proteins that employs approximately 1,750 people worldwide.

About Biotest AG

Biotest AG, Dreieich, Germany, is a company that researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has specialized in immunology and haematology. In its Pharmaceutical segment, Biotest develops and markets immunoglobulins, clotting factors and albumins based on human blood plasma. These are used for diseases of the immune system or hematopoietic system. In the Biotherapeutic segment, Biotest researches in the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and blood cancer. The Diagnostic segment spans reagents and serology and microbiology systems which are predominantly used in hygiene control, as well as serology, used, for example, in blood transfusions. Biotest has around 1,750 employees worldwide and its shares are listed in the Frankfurt Stock Exchange's Prime Standard.


'/>"/>
SOURCE Biotest Pharmaceuticals Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
2. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... PARIS , April 27, 2016 ... system disorders, today announces the appointment of Catherine Moukheibir as ... succeed MedDay,s previous Chairman, Jean Jacques Garaud , who ... The change is effective immediately. Catherine started her ... Boston and London .  She ...
(Date:4/26/2016)... ... April 26, 2016 , ... The European Patent ... selected as one of three finalists for the European Inventor Award 2016 in the ... prize will be announced at a ceremony in Lisbon on June 9th. , The ...
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., a ... round of financing. Healthy investor interest drove significant oversubscription of the original $1.5M ... known as biosimilars, to the advanced preclinical stages. , Chief Executive Officer and President, ...
(Date:4/26/2016)... ... April 26, 2016 , ... The Institute for Venture Science ... of pre-proposal competition for scientific grants. , The IVS funds promising ideas that ... highest potential to replace paradigms that have outlived their usefulness. All areas of ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):